<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Oncology | CSE Tracker</title>
    <link>https://master--youthful-lamport-190a0e.netlify.app/tag/20210506oncology/</link>
      <atom:link href="https://master--youthful-lamport-190a0e.netlify.app/tag/20210506oncology/index.xml" rel="self" type="application/rss+xml" />
    <description>Oncology</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Thu, 06 May 2021 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://master--youthful-lamport-190a0e.netlify.app/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_2.png</url>
      <title>Oncology</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/tag/20210506oncology/</link>
    </image>
    
    <item>
      <title>The 4th Stat4Onc Annual Symposium (2021)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210506the-4th-stat4onc-annual-symposium-2021/</link>
      <pubDate>Thu, 06 May 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210506the-4th-stat4onc-annual-symposium-2021/</guid>
      <description>&lt;p&gt;Topics for this symposium include big data and genomics, novel dose-finding designs, umbrella/basket designs, drug combinations, immune-based oncology, and engagement of under-representative population in oncology research.&lt;br&gt;
&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Early registration Deadline: Mar 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Advancing Early Stage Oncology Research with Adaptive Designs and Master Protocols</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200929advancing-early-stage-oncology-research-with-adaptive-designs-and-master-protocols/</link>
      <pubDate>Tue, 29 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200929advancing-early-stage-oncology-research-with-adaptive-designs-and-master-protocols/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Improved determination of the maximum tolerated dose, comparing different designs for dose selection&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Advantages of basket trial design for finding the most appropriate indication(s)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Current regulatory positions and outlook of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human use (ICH)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Operational implications of different designs&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Companion Diagnostics and Clinical Development in Oncology: A Statistical Perspective</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200917companion-diagnostics-and-clinical-development-in-oncology-a-statistical-perspective/</link>
      <pubDate>Thu, 17 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200917companion-diagnostics-and-clinical-development-in-oncology-a-statistical-perspective/</guid>
      <description>&lt;p&gt;This webinar provided a discussion around the need for integration of biomarker and IVD validation in clinical development, with a focus in oncology and companion diagnostics. It highlighted how flawed analytical and/or clinical validation can jeopardize a biomarker’s and drug’s clinical utility and showcase why biomarkers deserved statistical rigor throughout the development and validation process.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Clinical Endpoints and Treatment Effect in Immuno-Oncology</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707clinical-endpoints-and-treatment-effect-in-immuno-oncology/</link>
      <pubDate>Tue, 07 Jul 2020 11:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707clinical-endpoints-and-treatment-effect-in-immuno-oncology/</guid>
      <description>&lt;p&gt;In this webinar the speakers reviewed:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Adaptations to tumor response and progression criteria for immune therapies. Survival may be the endpoint of choice for clinical trials in some tumor types, but presence of delayed treatment effects and non-proportional hazards may complicate evaluation of treatment benefits.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Statistical methods to best describe and test for treatment effects in immuno-oncology randomized clinical trials.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
  </channel>
</rss>
